Botswana
Tuberculosis profile
| High HIV burden |
Population  2012 2 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.42 (0.11–0.92) 21 (5.5–46)
Mortality (HIV+TB only) 0.93 (0.74–1.1) 46 (37–57)
Prevalence  (includes HIV+TB) 6.9 (3.1–12) 343 (157–600)
Incidence  (includes HIV+TB) 8.2 (7.3–9.1) 408 (364–454)
Incidence (HIV+TB only) 5.1 (4.5–5.6) 253 (226–281)
Case detection, all forms (%) 75 (68–84)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 2 426 (42) Relapse 376 (86)
Smear-negative 743 (13) Treatment after failure 38 (9)
Smear-unknown / not done 1 465 (25) Treatment after default 24 (5)
Extrapulmonary 1 151 (20) Other 0 (0)
Other 0 (0)      
Total new 5 785   Total retreatment 438  
           
Other (history unknown) 0        
Total new and relapse 6 161   Total cases notified 6 223  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.2 1.2 1.2
Age < 15 103 332 100
Laboratories 2012
Smear (per 100 000 population) 2.6
Culture (per 5 million population) 2.5
Drug susceptibility testing (per 5 million population) 2.5
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 81   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 71  
Retreatment 70  
TB/HIV 2012 Number (%)
TB patients with known HIV status 5 940 (95)
HIV-positive TB patients 3 759 (63)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 3 374 (90)
HIV-positive TB patients on antiretroviral therapy (ART) 2 450 (65)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 2.5 (1.5–3.5) 6.6 (2.4–11)
MDR-TB cases among notified pulmonary
TB cases
120 (70–160) 29 (11–47)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 349 (14%) 149 (34%) 637
Laboratory-confirmed MDR-TB cases 21 18 53
Patients started on MDR-TB treatment     58
Financing TB control 2013
National TB programme budget (US$ millions) 20
% Funded domestically 67%
% Funded internationally 4%
% Unfunded 29%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-23 Data: www.who.int/tb/data